|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AG14
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:CASNumber
|
1004316-88-4
|
|
gptkbp:component
|
gptkb:Symtuza
gptkb:Evotaz
gptkb:Genvoya
gptkb:Stribild
|
|
gptkbp:contraindication
|
gptkb:phenytoin
gptkb:rifampin
gptkb:carbamazepine
phenobarbital
|
|
gptkbp:drugClass
|
CYP3A inhibitor
|
|
gptkbp:halfLife
|
3-4 hours
|
|
gptkbp:hasInChIKey
|
QMNWQZZUMQWQSF-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C40H53N7O5S2
|
|
gptkbp:hasSMILES
|
CC(C)C1=NC2=CC(=C(C=C2N1)N3CCN(CC3)C(=O)NC4=CC=CC=C4)C5=CC=CC=C5S(=O)(=O)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB04876
|
|
gptkbp:indication
|
pharmacokinetic enhancer for HIV therapy
|
|
gptkbp:legalStatus
|
patented
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:mechanismOfAction
|
inhibits CYP3A enzymes to boost plasma concentrations of co-administered drugs
|
|
gptkbp:metabolism
|
gptkb:CYP3A
gptkb:CYP2D6
|
|
gptkbp:molecularWeight
|
776.0
|
|
gptkbp:name
|
gptkb:Cobicistat
|
|
gptkbp:PubChem_CID
|
gptkb:DB04876
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
jaundice
rash
increased serum creatinine
|
|
gptkbp:status
|
true
|
|
gptkbp:substrate
|
gptkb:P-glycoprotein
|
|
gptkbp:synonym
|
gptkb:GS-9350
Tybost
|
|
gptkbp:target
|
gptkb:CYP3A5
gptkb:P-glycoprotein
gptkb:CYP2D6
gptkb:CYP3A4
|
|
gptkbp:bfsParent
|
gptkb:vildagliptin
|
|
gptkbp:bfsLayer
|
6
|